Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2018 Jun:139:72-78.
doi: 10.1016/j.rmed.2018.04.015. Epub 2018 May 5.

Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry

Robert P Baughman  1 , Oksana A Shlobin  2 , Athol U Wells  3 , Esam H Alhamad  4 , Daniel A Culver  5 , Joseph Barney  6 , Francis C Cordova  7 , Eva M Carmona  8 , Mary Beth Scholand  9 , Marlies Wijsenbeek  10 , Sivagini Ganesh  11 , Surinder S Birring  12 , Vasilis Kouranos  3 , Lanier O'Hare  6 , Joanne M Baran  5 , Joseph G Cal  4 , Elyse E Lower  13 , Peter J Engel  14 , Steven D Nathan  2
Affiliations
Free article
Multicenter Study

Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry

Robert P Baughman et al. Respir Med. 2018 Jun.
Free article

Abstract

Background: Pulmonary hypertension (PH) is a significant cause of morbidity and mortality in sarcoidosis. We established a multi-national registry of sarcoidosis associated PH (SAPH) patients.

Methods: Sarcoidosis patients with PH confirmed by right heart catheterization (RHC) were studied. Patients with pulmonary artery wedge pressure (PAWP) of 15 mmHg or less and a mean pulmonary artery pressure (mPAP) ≥ 25 Hg were subsequently analyzed. Data collected included hemodynamics, forced vital capacity (FVC), diffusion capacity of carbon monoxide (DLCO), chest x-ray, and 6-min walk distance (6MWD).

Results: A total of 176 patients were analyzed. This included 84 (48%) cases identified within a year of entry into the registry and 94 (53%) with moderate to severe PH. There was a significant correlation between DLCO percent predicted (% pred) andmPAP (Rho = -0.228, p = 0.0068) and pulmonary vascular resistance (PVR) (Rho = -0.362, p < 0.0001). PVR was significantly higher in stage 4 disease than in stage 0 or 1 disease (p < 0.05 for both comparisons). About two-thirds of the SAPH patients came from the United States (US). There was a significant difference in the rate of treatment between US (67.5%) versus non-US (86%) (Chi Square 11.26, p = 0.0008) sites.

Conclusions: The clinical features of SAPH were similar across multiple centers in the US, Europe, and the Middle East. The severity of SAPH was related to reduced DLCO. There were treatment differences between the US and non-US centers.

Keywords: Epidemiology; Sarcoidosis; Sarcoidosis associated pulmonary hypertension.

PubMed Disclaimer

Publication types

MeSH terms